Expected earnings - Fate Therapeutics Inc.

August 12, 2025 05:31:14 am

Source: US Earnings Reports

Fate Therapeutics Inc. (FATE) is expected to report $-0.35 for Q2 2025

Fate Therapeutics Inc.

NASDAQ: FATE

FATE Trading

-8.33% G/L:

$1.815 Last:

315,500 Volume:

$1.86 Open:

mwn-ir Ad 300

FATE Latest News

May 13, 2026 08:30:00 am

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

May 11, 2026 08:30:00 am

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

May 05, 2026 08:30:00 am

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

May 04, 2026 09:00:00 am

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

FATE Stock Data

Market Cap$128,041,041

Float108,996,378

Insiders Ownership1.54%

Institutions45

Short PercentN/A

IndustryBiotechnology & Life Sciences

SectorHealthcare

Websitehttps://www.fatetherapeutics.com

CountryUS

CitySan Diego

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App